Aurobindo Pharma

PRESS ROOM

Aurobindo granted license by BMS for two ARV products.

Aurobindo's receives US FDA approval for Lisinopril and Hydrochlorothiazide Tablet

Aurobindo receives first NDA approval for ARV product from US FDA

Health Canada approves Aurobindo's Citalopram

Aurobindo's receives final approval of Mirtazapine ODT 45 mg for the US Market

Aurobindo receives Final approval for Lisinopril tablets

Aurobindo Pharma acquires UK based Milpharm

Robust growth in Q3 profits driven by strong formulations exports; registers record turnover of Rs.4169.7 million.

UK MHRA approval received for Unit XII facility

Aurobindo receives first generic approval from US FDA for Nevirapine Oral Suspension

Aurobindo receives first tentative approval for Stavudine Oral Solution from US FDA

Aurobindo's 6 ARV products in World Health Organization (WHO) Pre-qualification list

Aurobindo selected for Patent Appreciation Award by IDMA

Aurobindo's receives final approval of Mirtazapine Orally Disintegrating Tablets

Aurobinoo's product included in World Health Organization (WHO) Pre-qualification list

Aurobindo receives approval for Cephalexin Capsules by US FDA

Aurobindo receives approval for Amoxicillin Tablets & Capsules

Aurobindo receives tentative approval for Lamivudine Oral Solution from UD FDA

Aurobindo Q2 Revenue Improves to Rs.3271 Million.
- growth of over 20%

Aurobindo gets EDQM approval for Flucloxacillin Sodium

US FDA grants tentative approval for Aurobindo's Sertraline

US FDA grants approval for Aurobindo's zidovudine

Aurobindo receives tentative approval for zidovudine tablet

Aurobindo�s products included in World Health Organization (WHO) Pre-qualification list

Aurobindo�s scientist conferred award

Aurobindo posts revenue of Rs.2807 Million in Q1.

Aurobindo gets EDQM approval for Domperidone & Domperidone Maleate

Canadian authority approves Aurobindo�s facilities

Aurobindo Pharma gets US FDA nod for lamivudine and zidovudine combination tablets

Aurobindo receives - first generic approval of Efavirenz

Aurobindo announces approval of Stavudine tablets

Aurobindo records revenue of Rs.11592 Million. Record facility approvals, DMFs/ANDAs filings and significant R & D expenses weigh on Aurobindo's bottom line

Aurobindo receives second ANDA approval from US FDA for PEPFAR

Aurobindo receives the first ARV approval from US FDA

USFDA approval received for Unit VIII Facility

Aurobindo receives NABL approval for its Clinical Laboratory

Aurobindo records improved performance quarter on quarter
Successful USFDA Inspection of one more Unit
Obtains 3^rd product approval from USFDA

Aurobindo in Forbes list
Best under a Billion - Asia's Rising Companies

Aurobindo receives US FDA approval for Citalopram
A robust generic product portfolio to unveil.

Aurobindo obtains two product approvals from US FDA
Records Rs.272 crore turnover in Q2

First product approval from US FDA received
Foray into Regulated Market crosses first major milestone

Company scientists conferred awards

Speech by the Chairman, Mr. P. V. Ramaprasad Reddy at the Annual General Meeting on 31^st July 2004

Aurobindo posts Rs.2873 Millions sales and Rs.180 Million profit

Aurobindo net profit at Rs. 127 crs surges by 23%

UK MHRA (UK MCA) approval received for Unit 3

Subscription to preferential issue of equity shares

Aurobindo Q3 PAT grows by 68% Exports soar to 51% of sales

Aurobindo gets its first CoS approval from EDQM & files DMF for Citalopram

Aurobindo's Q2 Net Profit jumps to Rs.321.5 million, spurt by 57%

Preferential Issue of Equity Shares

Aurobindo net profit spurts by 52.75% in Q1

Aurobindo crosses the landmark Net Profit of Rs.100 crores

Aurobindo's demonstration of R&D leadership in cephalosporins

Aurobindo Pharma launches cefepime

Second quarter profit jumps 41.13%

Aurobindo implementing ERP package

First quarter profit jumps 34%

Aurobindo posts Net Profit of Rs. 68.51 crores

Noted Cardiologist Dr. I. Satyamurthy joins Aurobindo Board

Aurobindo Pharma wins award for the best bulk drug company

Shares allotted to Templeton

Brazilian GMP certification received for the speciality generic formulations unit

Aurobindo Pharma acquires equity in Ranit Pharma

Mr. Lanka Srinivas inducted as Additional Director on Board of Aurobindo Pharma

Aurobindo Pharma launches Aztreonam for the first time in India

Aurobindo Pharma & Citadel promote a joint venture

Aurobindo Pharma welcomes excise duty exemption on anti-HIV drugs in budget

Aurobindo launches Cefactam (Cefoperazone plus Salbactam)

4^th generation Cephalosporin – Cefpirome launched

Impressive Q3 performance

Aurobindo shareholders approve Rs.125 crore Private Placement

Templeton to pick up equity

Aurobindo Pharma Board approves Rs. 125 crore private placement

Aurobindo Pharma launches two more antiretroviral products for HIV treatment

Restructuring on track

Aurobindo introduces two more drugs for treatment of Aids

Imunus Aurobindo launches two new anti-aids drugs

Aurobindo Pharma slashes prices of anti-aids drugs

Restructuring of Facilities

Income crosses Rs. 1000 crore land mark

www.aurobindo.com

Hyderabad, 18^th January, 2006

AUROBINDO'S TWO PRODUCTS INCLUDED IN WORLD HEALTH ORGANIZATION (WHO) PRE-QUALIFICATION LIST

Aurobindo Pharma Limited is delighted to announce that the World Health Organization (WHO), Geneva, has included two more of its anti-retroviral products viz. Nevirapine oral suspension 50 mg/5 ml and Stavudine for oral solution 1mg/ml in the Pre-qualification list.

This inclusion takes the count of Aurobindo's products in the Pre-qualification list to twelve. This is the first time that a generic version of Nevirapine oral suspension has been included in the Prequalification list. As for Stavudine for oral solution, it is also the first time that this product has appeared on the Prequalification list. Both these products are used as a part of first time line treatment in pediatric AIDS.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company has received approvals for several facilities from leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa. The company�s robust product portfolio is spread over 6 major therapeutic/product areas encompassing (Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) around 65 APIs in the non-antibiotics and 55 APIs in the antibiotic segment. The Company is marketing these products globally, in over 100 countries.

Top

________________________________________________________________